644 - Outcome of patients with colorectal liver metastasis: analysis of 1613 consecutive cases

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Aetiology, epidemiology, screening and prevention
Colon and Rectal Cancer
Basic Scientific Principles
Presenter Jianmin Xu
Authors J. Xu, D. Zhu, L. Ren, Y. Wei, H. Wu, Y. Zhong
  • Department Of General Surgery, Zhongshan Hospital Fudan University, 200032 - Shanghai/CN



To evaluate the long-time outcome of patients with colorectal liver metastasis (CRLM) undergoing different types of therapy and identify prognosis factors.


From 2000 to 2010, 1613 consecutive patients with CRLM were identified. Clinicopathological and outcome data were collected and analyzed by univariate and multivariate analyses.


Synchronous liver metastasis (SLM), female, grade III-IV, T4 and N positive of primary tumor, bilobar disease, number of liver metastases ≥ 4, size of largest liver metastases ≥ 5 cm, serum CEA level ≥5 ng/ml and CA19-9 level ≥ 37u/ml were the predictors of adverse outcome using univariate analysis. The median survival and five-year survival rate for patients after resection of liver metastases was 49.8 months and 47%, better than that for those after other therapy. In addition, patients without treatment had the poorest survival. Sixty-four initially unresectable patients underwent surgery after conversion therapy with a median survival of 36.9 months and a five-year survival of 30%. By multivariate analysis, SLM, poorly differentiated primary tumor, number of liver metastases ≥ 4, size of largest liver metastases ≥ 5 cm, and no surgical treatment of liver metastases were found to be independent predictors of poor survival.


Patients with CRLM could get long-term survival benefit from different types of therapy, and resection of liver metastases was the optimal strategy. A predictive model using these above five factors may be of use in stratifying patients who may benefit from intensive surveillance and adjuvant therapy.


All authors have declared no conflicts of interest.